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ABSTRACT
Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal 
overall survival (OS) and to date no molecular markers are available to guide patient 
management. This study aimed to identify a prognostic miRNA signature in MPM 
patients who did not undergo tumor resection. Whole miRNA profiling using a 
microarray platform was performed using biopsies on 27 unresected MPM patients 
with distinct clinical outcome: 15 patients had short survival (OS<12 months) and 
12 patients had long survival (OS>36 months). Three prognostic miRNAs (mir-
99a, let-7c, and miR-125b) encoded at the same cluster (21q21) were selected for 
further validation and tested on publicly available miRNA sequencing data from 72 
MPM patients with survival data. A risk model was built based on these 3 miRNAs 
that was validated by quantitative PCR in an independent set of 30 MPM patients. 
High-risk patients had shorter median OS (7.6 months) as compared with low-risk 
patients (median not reached). In the multivariate Cox model, a high-risk score was 
independently associated with shorter OS (HR=3.14; 95% CI, 1.18–8.34; P=0.022). 
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Our study identified that the downregulation of the miR-99a/let-7/miR-125b miRNA 
cluster predicts poor outcome in unresected MPM.
INTRODUCTION
Malignant Pleural Mesothelioma (MPM) originates 
from mesothelial cells that cover the pleura. The most 
common cause of this disease is the exposure to the 
asbestos fiber; indeed, MPM is predominant in areas 
where there are heavy or chemical industries, shipyards 
and oil refineries known to be activities related to asbestos 
usage. MPM is characterized by a long latency and its 
incidence is expected to increase in some industrialized 
countries over the next 5-10 years [1]. Long-term survival 
rate of patients with MPM is generally poor with a median 
overall survival (OS) of 9-11 months [2].
MPM can be histologically classified into three 
major subtypes: epithelioid, sarcomatoid and biphasic. 
Most MPM patients are considered not suitable for a 
multimodal therapeutic approach and the majority of 
patients are treated with palliative chemotherapy. Patients 
are deemed suitable for radical treatment with curative 
intent if the following criteria are met: epithelioid 
histology, absence of lymph nodal involvement, 
technically resectable disease, and ability to tolerate 
major pulmonary surgery. In Europe, multimodal therapy 
including induction with platinum-based chemotherapy, 
extra-pleural pneumonectomy (EPP) and radiation 
therapy is generally performed in selected patients in 
specialized hospitals. As this technique is associated with 
relevant perioperative morbidity and mortality, another 
surgical approach, pleurectomy with decortication (P/D), 
emerged as a lung-sparing procedure suitable for the 
radical treatment of patients with good performance status 
and early stage of disease [3]. Globally, while several 
studies have been conducted with the aim of addressing 
harms and benefits of surgery in MPM, its current role 
remains controversial, mostly due to difficulties in 
patient enrollment and different expertise across surgical 
departments; notably, a feasibility trial designed to 
clarify the role of P/D (MARS2) is currently ongoing 
[4]. Cisplatin with pemetrexed showed longer median OS 
as compared with cisplatin alone and is considered the 
standard of care for patients with unresectable MPM [5]. 
In the MAPS trial, the addition of bevacizumab to cisplatin 
and pemetrexed demonstrated a significant increase in 
the OS compared with the standard treatment [6]. There 
is no established second-line standard of care, although 
single-agent regimens with gemcitabine or vinorelbine 
represent a suitable approach, as well as re-challenge 
with pemetrexed-based chemotherapy in case of good and 
sustained response during first-line treatment [3].
Among the MPM patients who could not undergo 
surgery with radical intent, there is a relatively small 
subgroup whose OS is greater than 3 years; therefore, 
taking into account this observation, we interrogated 
whether specific markers were able to predict prognosis 
and define which patients might benefit from aggressive 
approaches, eventually including multi-modality 
treatments. To date, numerous studies reported how 
expression level of specific miRNAs, small noncoding 
RNA involved in gene expression regulation, is able to 
precisely predict prognosis in MPM [7–12]. Recently, 
Kirschner and colleagues reported the first miRNA 
prognostic signature in surgically resected MPM patients 
[13]. Specifically, the authors identified 6 differentially-
expressed miRNAs between long and short survivors in 
a cohort of patients who underwent surgery. However, a 
significant limitation of this study is represented by the 
low number of MPM patients who are deemed to be 
adequate candidates for surgery.
We hypothesized that miRNA expression profiling 
might identify relevant markers associated with clinical 
outcome in patients with unresectable MPM, which 
represent the majority of cases observed in clinical 
practice. In the present study, we first performed a miRNA 
microarray expression profiling using formalin-fixed 
paraffin embedded (FFPE) tumor biopsy samples from 
patients affected by MPM who did not undergo surgery 
and then selected miRNAs with prognostic value were 




Tumor biopsy samples from patients with 
unresectable MPM were divided in two independent sets: 
training set (TS) and validation set (VS), consisting of 27 
and 30 samples respectively. Clinical and demographic 
characteristics of patients included are shown in Table 
1. There were no significant differences according to 
age, gender, smoking history, asbestos exposure or 
histopathological subtype between both sets. About half of 
patients in each set were considered long-term survivors.
MiRNA microarray profiling yielded 
differentially-expressed miRNAs
All 27 tumor samples corresponding to the TS and 
4 nonmalignant pleural samples were hybridized to the 
miRNA microarray, however two cases (1 long survivor 
and 1 normal control) failed the quality control step and 
were excluded from the analysis (Supplementary Figure 
1). Overall, the mean number of miRNAs expressed 
per sample was 297 and 116 miRNAs were expressed 
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in all samples. MiRNAs with more than 30% missing 
data across all samples were filtered out and a total of 
259 human miRNAs were retained in the final analysis. 
Among the final 259 miRNAs, 91 miRNAs were found 
differentially expressed in 26 MPMs as compared to 3 
nonmalignant pleura at p-value<0.05 (Mann-Whitney 
U test). Specifically, 58 miRNAs were significantly 
up-regulated (fold change>2), whereas 33 were down-
regulated in tumor tissues (fold change<0.5), as shown in 
Table 2. Supervised clustering based on 64 differentially 
expressed miRNAs at p-value<0.01 is shown in Figure 1.
Hierarchical clustering yielded two major 
clusters associated with clinical outcome
In the TS, hierarchical clustering analysis based 
on 259 miRNAs yielded two major tumor clusters 
(Figure 2A). There was no statistically significant 
difference in age, gender or histological subtype among 
patients classified according to these clusters (data not 
shown). Interestingly, patients classified in cluster 2 had 
significantly shorter median OS (7 months) as compared 
with patients categorized in cluster 1 (median OS not 
reached, Log-rank p=0.035, Figure 2B).
To identify individual miRNAs significantly 
associated with clinical outcome, we performed class-
comparison analysis among short and long survivors. We 
identified 35 differentially-expressed miRNAs at a t-test 
p-value<0.05 among short and long survivors that were 
also associated with clinical outcome in the univariate 
analysis (Cox regression p-value<0.05, Table 3).
A 3-miRNA prognostic signature was validated 
using TCGA data
In order to validate our findings and to assess the 
prognostic value of these 35 miRNAs in an independent 
dataset, we used publicly available miRNA sequencing 
Table 1: Characteristics of patients included in the training set and the validation set
Characteristics




 Median (SD) 67.9 (± 6.5) 69.5 (± 8.5) 68.7 (± 7.6) 0.540†
Sex –n (%)
 Male 22 (81%) 25 (83%) 47 (82.5%)
 Female 5 (19%) 5 (17%) 10 (17.5%) 0.854‡
Smoking –n (%)
 Smokers 18 (67%) 19 (63%) 37 (65%)
 Never smokers 9 (33%) 9 (30%) 18 (31.5%)
 Unknown 0 (0%) 2 (7%) 2 (3.5%) 0.391‡
Asbestos exposure –n (%)
 Yes 22 (81%) 20 (67%) 42 (74%)
 Unknown 5 (19%) 10 (33%) 15 (26%) 0.205‡
Histological subtype –n (%)
 Epithelioid 20 (74%) 21 (70%) 41 (72%)
 Sarcomatoid 3 (11%) 4 (13%) 7 (12%)
 Biphasic 3 (11%) 3 (10%) 6 (10.5%)
 Desmoplastic 0 (0%) 2 (7%) 2 (3.5%)
 Not typified 1 (4%) 0 (0%) 1 (2%) 0.555‡
Outcome –n (%)
Short survivor 15 (55.5%) 16 (53%) 31 (54%)
Long survivor 12 (44.5%) 14 (47%) 26 (46%) 0.866‡
†, Student’s t-test; ‡, Chi-square test.
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Table 2: MiRNAs differentially expressed between mesothelioma tumor and nonmalignant pleura
ID Average MPM Average pleura Fold change P-value
hsa-miR-4486 0.25 -2.87 8.66 0.0052
hsa-miR-4497 4.77 2.25 5.76 0.0099
hsa-miR-1181 0.71 -1.66 5.17 0.0052
hsa-miR-1273e -0.68 -3.03 5.12 0.0081
hsa-miR-4465 3.11 0.77 5.04 0.0052
hsa-miR-4430 2.91 0.64 4.82 0.0052
hsa-miR-513b 0.03 -2.06 4.25 0.0149
hsa-miR-4653-3p 2.53 0.45 4.23 0.0052
hsa-miR-1224-5p 3.03 0.96 4.21 0.0052
hsa-miR-4462 0.07 -1.94 4.02 0.0052
hsa-miR-4428 2.57 0.60 3.92 0.0081
hsa-miR-3676-5p 5.89 3.95 3.83 0.0052
hsa-miR-6132 3.27 1.44 3.57 0.0099
hsa-miR-4734 0.20 -1.62 3.51 0.0065
hsa-miR-345-5p -1.43 -3.23 3.47 0.0052
hsa-miR-4656 0.54 -1.23 3.42 0.0052
hsa-miR-1273f 1.14 -0.63 3.42 0.0099
hsa-miR-1972 2.04 0.31 3.33 0.0065
hsa-miR-6075 0.46 -1.27 3.30 0.0065
hsa-miR-4721 3.70 1.98 3.29 0.0052
hsa-miR-1185-2-3p 0.49 -1.14 3.10 0.0052
hsa-miR-1233-1-5p 0.13 -1.49 3.08 0.0081
hsa-miR-4515 0.96 -0.63 3.02 0.0052
hsa-miR-197-5p -0.40 -1.98 2.99 0.0149
hsa-miR-4478 1.23 -0.35 2.99 0.0052
hsa-miR-513a-5p 1.27 -0.30 2.97 0.0052
hsa-miR-1185-1-3p 1.89 0.33 2.95 0.0052
hsa-miR-4695-5p 1.18 -0.38 2.95 0.0052
hsa-miR-4758-5p -0.25 -1.80 2.94 0.0052
hsa-miR-6076 2.01 0.48 2.89 0.0052
hsa-miR-3620-5p 0.09 -1.43 2.87 0.0065
hsa-miR-1471 1.59 0.10 2.82 0.0099
hsa-miR-4746-3p 1.63 0.15 2.78 0.0052
hsa-miR-4257 1.42 -0.05 2.78 0.0065
hsa-miR-762 4.21 2.74 2.76 0.0052
hsa-miR-1973 5.05 3.60 2.74 0.0052
hsa-miR-371a-5p 0.59 -0.85 2.71 0.0052
hsa-miR-4672 1.96 0.53 2.70 0.0081
hsa-miR-3940-5p 2.89 1.46 2.69 0.0052
hsa-miR-21-5p -1.05 -2.41 2.56 0.0219
hsa-miR-494 6.55 5.19 2.55 0.0099
(Continued )
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ID Average MPM Average pleura Fold change P-value
hsa-miR-3648 1.53 0.19 2.53 0.0081
hsa-miR-4322 -0.23 -1.56 2.51 0.0149
hsa-miR-3137 0.92 -0.37 2.44 0.0052
hsa-miR-6126 1.94 0.69 2.39 0.0065
hsa-miR-5585-3p 1.59 0.35 2.37 0.0081
hsa-miR-4745-5p 1.08 -0.09 2.24 0.0052
hsa-miR-3188 0.72 -0.44 2.23 0.0122
hsa-miR-671-5p 1.98 0.84 2.21 0.0378
hsa-miR-4728-5p 1.73 0.59 2.20 0.0081
hsa-miR-4417 0.75 -0.37 2.18 0.0065
hsa-miR-937-5p 2.87 1.76 2.16 0.0052
hsa-miR-574-5p 2.58 1.47 2.16 0.0450
hsa-miR-135a-3p 0.55 -0.55 2.14 0.0149
hsa-miR-3162-5p 4.62 3.54 2.11 0.0099
hsa-miR-4673 -0.49 -1.54 2.08 0.0099
hsa-miR-1290 -0.57 -1.61 2.05 0.0099
hsa-miR-3917 -0.40 -1.41 2.01 0.0219
hsa-miR-4778-5p -0.84 0.21 0.48 0.0264
hsa-miR-6090 6.36 7.42 0.48 0.0264
hsa-let-7i-5p 1.89 2.98 0.47 0.0317
hsa-miR-93-5p -1.52 -0.34 0.44 0.0264
hsa-let-7e-5p 1.11 2.31 0.44 0.0317
hsa-miR-483-5p 0.42 1.65 0.43 0.0122
hsa-miR-378a-3p -0.48 0.77 0.42 0.0181
hsa-let-7a-5p 3.79 5.09 0.41 0.0219
hsa-let-7g-5p 0.79 2.22 0.37 0.0181
hsa-let-7d-5p 0.59 2.07 0.36 0.0149
hsa-miR-151a-5p -1.33 0.25 0.34 0.0099
hsa-miR-125b-5p 1.91 3.60 0.31 0.0219
hsa-miR-342-3p -1.51 0.20 0.31 0.0099
hsa-miR-5703 1.10 2.81 0.30 0.0081
hsa-miR-199a-3p 0.42 2.14 0.30 0.0264
hsa-miR-320b 0.44 2.18 0.30 0.0052
hsa-miR-630 1.66 3.42 0.30 0.0081
hsa-miR-23a-3p 1.22 3.06 0.28 0.0052
hsa-miR-15b-5p 0.38 2.23 0.28 0.0181
hsa-miR-199a-5p -1.50 0.43 0.26 0.0378
hsa-miR-25-3p -1.06 0.93 0.25 0.0181
hsa-miR-320d 0.14 2.16 0.25 0.0052
hsa-miR-195-5p -0.88 1.19 0.24 0.0264
hsa-miR-92a-3p -1.32 0.75 0.24 0.0264
hsa-miR-320e -0.44 1.66 0.23 0.0052
(Continued )
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data from 72 MPM patients deposited in TCGA. Only 
12 miRNAs remained statistically associated with OS 
(Table 3 and Supplementary Table 1). Interestingly, the 
top 3 prognostic miRNAs (miR-99a, let-7c, and miR-
125b) were structurally associated by their genomic 
location on the long arm of chromosome 21 (21q21.1) 
and selected for further validations. In the TS, patients 
with low expression of miR-99a, let-7c, and miR-125b 
had significantly shorter median OS (2.9, 2.9 and 3.4 
months, respectively) as compared to patients with high 
expression of these miRNAs (median OS not reached, 
Figure 3A). Accordingly, in the TCGA dataset, patients 
with low expression of miR-99a, let-7c, and miR-125b 
had significantly shorter median OS (10.9 months for 
all three markers) as compared to patients with high 
expression (19.7, 19.7, and 24.1 months, Figure 3B).
The expression of miR-99a, let-7c, and miR-125b 
was assessed using qPCR in the TS and a close correlation 
was observed among the expression values generated 
by microarray and qPCR (Pearson r coefficient: 0.55; 
0.71 and 0.42 respectively, Supplementary Figure 2). 
In order to explore the hypothetical biological effect of 
these 3 miRNAs, we carried out a pathway enrichment 
analysis based on the validated gene targets of miR-99a, 
let-7c, and miR-125b. This analysis revealed that these 
miRNAs are significantly associated with pathways 
relevant in mesothelioma such as cell cycle, pluripotency 
of stem cells, HIF-1, ErbB and AMPK signaling pathways 
(Supplementary Table 2).
Validation of a miRNA prognostic signature by 
qPCR in an independent cohort
In the validation set, we observed that miR-
99a, let-7c, and miR-125b expression did not correlate 
with the histological type of mesothelioma (Mann-
Whitney p>0.05), whereas their expression values were 
significantly higher in long-surviving patients (Mann-
Whitney p<0.05, Supplementary Figure 3).
A miRNA signature was built based on the 
expression of miR-99a, let-7c, and miR-125b by 
calculating a risk score based on the sum of the 
expression of these miRNAs in the VS, weighted by the 
corresponding regression coefficients (β) derived from the 
Cox regression analysis in the TS, as previously reported 
[14]. The median risk score value was used as cutoff to 
classify the patients into high-risk or low-risk. In this 
VS, patients with a high-risk score had a significantly 
shorter median OS (7.6 months; 95% confidence interval, 
CI, 4.4–10.9) as compared with low-risk patients (median 
not reached, log-rank p=0.042, Figure 4). The OS rates at 
24 months for high- and low-risk patients were 27.7% ± 
11.4 and 66.7% ± 11.2, respectively. In the multivariate 
Cox model (adjusted by age and histological subtype) a 
high-risk score remained as an independent prognostic 
marker for OS (Hazard Ratio (HR) =3.14; 95% CI, 1.18–
8.34; p=0.022). The prognostic value of these 3 miRNAs 
(miR-99a, let-7c, and miR-125b) encoded at the 21q21 
was therefore validated in an independent set of MPM.
Copy number analysis of miR-99a/let-7c/miR-
125b locus
Copy number variation (CNV) analysis of the miR-
99a/let-7c/miR-125b locus (21q21.1) was performed 
using droplet digital PCR (ddPCR) on 44 out of 57 
patients enrolled (16/27 TS and 28/30 VS) divided as 
follows: 17 long survivors (LS) and 27 short survivors 
(SS) patients. In particular, the miR-99a/let-7c/miR-
125b locus data was normalized using two genes: 
RNA binding motif protein 11 (RBM11) targeting the 
centromere locus on chromosome 21 (to discern 21 
monosomy) and adaptor-related protein complex 3, 
beta 1 subunit (AP3B1) mapping on 5q14.1. The CNV 
analysis reported 21q21.1 locus mean values in the two 
MPM sub-populations as follows: 1.91 (range: 1.62-
2.27) and 1.88 (range: 1.19-2.31) in LS and SS patients, 
respectively (Supplementary Figure 4). In particular, two 
ID Average MPM Average pleura Fold change P-value
hsa-miR-320c 1.26 3.54 0.21 0.0081
hsa-let-7b-5p 3.88 6.26 0.19 0.0052
hsa-let-7c 1.79 4.25 0.18 0.0065
hsa-miR-22-3p -1.27 1.42 0.16 0.0099
hsa-miR-99a-5p -1.19 1.69 0.14 0.0219
hsa-miR-1260b -0.98 2.09 0.12 0.0052
hsa-miR-150-5p -1.43 1.77 0.11 0.0099
hsa-miR-451a 0.13 5.10 0.03 0.0052
List of the 91 miRNAs found differentially expressed between 26 MPMs and 3 nonmalignant pleura (p-value<0.05) by microarray 
analysis. Specifically, 58 miRNAs were significantly up-regulated (fold change>1.5), whereas 33 were down-regulated in tumor tissues 
(fold-change<0.5).
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Figure 1: Supervised clustering of differentially expressed miRNAs among mesothelioma and nonmalignant pleural 
samples. Samples (26 MPM tumors and 3 nonmalignant pleura) are depicted in columns and miRNAs in rows. Substantially elevated 
(red) or decreased (green) expression of the miRNAs is observed for individual tumors. Samples and arrays were mean-centered, centroid 
linkage clustering using Cluster v.3.0 and visualization using Tree-View software.
SS patients showed a copy number ratio lower than 1.5, 
however when data were normalized based on RBM11 
that targets the centromere, the obtained copy number 
ratio was diploid (1.97 and 2.35). These results suggested 
a potential imbalance between the two chromosomes (21 
monosomy or 5 extra-copies) rather than a loss of a copy 
of the locus.
DISCUSSION
MiRNA expression profiling represents a powerful 
tool for identifying prognostic markers in cancer, including 
MPM [10]. However, to the best of our knowledge, no 
miRNA signature has ever been identified for predicting 
prognosis in unresected MPM patients. Toward this aim, in 
the present study we screened the whole miRNA profile in 
a cohort of 26 MPM patients who did not undergo radical 
surgery, in order to identify novel prognostic markers. The 
analysis identified 46 miRNAs differentially expressed 
in MPM specimens, some of which had been previously 
reported in MPM, such as downregulation of let-7 in 
MDM2 positive MPM tumors [15], and low expression 
of miRNA23a-3p in a subgroup of MPM long survivors 
after surgery [13].
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Figure 2: Unsupervised hierarchical clustering of miRNA expression in mesothelioma tumors. (A) Two major clusters of 
tumors were identified by unsupervised clustering analysis based on 259 miRNAs expressed in all tumors. (B) Kaplan-Meier plot of overall 
survival according to the cluster subgroups.
In order to investigate miRNAs with prognostic 
value, the 26 MPM patients were divided based on whether 
they had short or long survival. Class-comparison analysis 
of miRNA expression among short and long survivors 
yielded 35 differentially-expressed miRNAs, and 32 out 
of 35 were significantly associated with clinical outcome 
in the univariate analysis (p-value<0.05). The prognostic 
value of 12 miRNAs out of these 35 was validated in an 
independent dataset composed of 72 MPM patients using 
publicly available miRNA sequencing data from TCGA.
Notably, the top three prognostic miRNAs (miR-
99a, let-7c, and miR-125b) among those 12 validated 
miRNAs, were structurally associated by their genomic 
location on the long arm of chromosome 21 (21q21.1).
These 3 miRNAs might play a tumor suppressor 
role, as they have been found to be down-regulated in 
distinct tumor types. In particular, their down-modulation 
has been described in lung cancer linked to a homozygous 
deletion at 21q21.1 [16], although in our cohort of samples 
we did not find any CNVs at the miR-99a/let-7c/miR-
125b cluster. Interestingly, miR-99a is among the most 
frequently down-regulated miRNAs in cancer, and its low 
expression has been linked to increased proliferation in 
different tumor types such as head and neck carcinoma 
and cervical carcinoma, as well as lung cancer, breast 
cancer and melanoma [17–20]. Likewise, let-7c is down-
regulated in a variety of cancer types such as lung and 
prostate cancer, melanoma and Wilms’ tumors; indeed, 
lack of let-7c expression is associated with increased cell 
proliferation in both prostate and lung cancer [21, 22]. 
Similarly, low expression of miR-125b has been described 
in epithelial ovarian cancer and oral cavity squamous 
cell carcinoma [23, 24]. In addition, two recent studies 
showed concomitant downregulation of the miR-99a/
let-7c/miR-125b cluster both in cholangiocarcinoma and 
prostate cancer [25, 26]. In particular, downregulation 
of this cluster has been linked to inflammation through 
the activation of IL6/STAT3 pathway [26]. Association 
between inflammation and MPM has already been 
investigated, and evidence suggests that activation of IL6 
plays a role in cell proliferation and chemo-resistance [27, 
28]. A further potential demonstration of the role of the 
miR-99a/let-7c/miR-125b cluster as a tumor suppressor 
might be found in patients affected by Down syndrome, 
a genetic disorder characterized by chromosome 21 
trisomy [29]. In this regard, Forés-Martos and colleagues 
hypothesized that the low incidence rate of solid tumors in 
subjects with Down syndrome might be related to the gain 
of copies of this miRNA cluster, located on chromosome 
21 [19].
A miRNA signature was built based on the 
expression of miR-99a, let-7c, and miR-125b, and tested 
in an independent set of MPM samples in which patients 
were classified as high-risk or low-risk according to their 
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Table 3: MiRNAs significantly associated with survival
ID Average SS Average LS ttest p-value Fold Change Cox HR Cox p-value
TCGA dataset 
validation
miR-99a-5p -2.07 -0.15 0.0031 0.26 0.42 0.0014 yes
let-7c 1.28 2.37 0.0066 0.47 0.32 0.0014 yes
miR-125b-5p 1.31 2.62 0.0084 0.40 0.41 0.0010 yes
miR-26b-5p -1.35 -0.13 0.0070 0.43 0.45 0.0022 yes
miR-371a-5p 0.79 0.36 0.0120 1.35 42.57 0.0010 yes
miR-23b-3p -0.28 1.00 0.0201 0.41 0.53 0.0036 yes
miR-107 -0.66 0.01 0.0275 0.63 0.27 0.0040 yes
miR-26a-5p 0.06 1.02 0.0370 0.51 0.50 0.0041 yes
miR-30b-5p -2.13 -1.10 0.0126 0.49 0.46 0.0045 yes
miR-1185-1-3p 2.07 1.69 0.0107 1.30 11.73 0.0050 yes
miR-29c-3p -1.21 -0.26 0.0497 0.52 0.56 0.0120 yes
miR-342-3p -1.82 -1.14 0.0333 0.62 0.40 0.0232 yes
miR-652-5p -0.84 -1.28 0.0165 1.36 17.49 0.0010 opposite
miR-1236-5p 0.69 0.37 0.0010 1.25 52.14 0.0020 no
miR-130a-3p -0.37 1.08 0.0018 0.37 0.40 0.0010 no
miR-937-5p 3.09 2.61 0.0023 1.40 12.21 0.0007 no
miR-1224-5p 3.25 2.78 0.0033 1.39 35.63 0.0010 no
miR-197-5p 5.23 4.84 0.0054 1.31 11.85 0.0018 no
miR-25-3p -1.43 -0.63 0.0054 0.57 0.13 0.0017 no
let-7d-5p 0.14 1.11 0.0085 0.51 0.23 0.0002 no
miR-642a-3p 5.53 5.11 0.0085 1.34 22.97 0.0020 no
miR-320e -0.71 -0.13 0.0142 0.67 0.27 0.0094 no
miR-3137 1.10 0.70 0.0144 1.33 17.53 0.0020 no
miR-16-5p 1.33 2.28 0.0153 0.52 0.2917 0.0002 no
miR-151a-5p -1.71 -0.88 0.0155 0.57 0.34 0.0030 no
miR-3162-5p 4.92 4.27 0.0195 1.57 14.91 0.0020 no
miR-1229-5p 3.40 3.02 0.0289 1.30 6.37 0.0070 no
let-7b-5p 3.60 4.21 0.0302 0.66 0.24 0.0023 no
miR-939-5p 3.06 2.72 0.0329 1.27 17.76 0.0014 no
let-7a-5p 3.49 4.15 0.0373 0.63 0.33 0.0049 no
miR-671-5p 2.31 1.61 0.0379 1.62 7.4268 0.0117 no
miR-15b-5p 0.04 0.77 0.0384 0.60 0.40 0.0075 no
miR-1185-2-3p 0.65 0.31 0.0394 1.27 7.61 0.0130 no
let-7f-5p 2.35 3.01 0.0446 0.64 0.31 0.0076 no
miR-22-3p 0.85 1.65 0.0469 0.58 0.47 0.0232 no
List of miRNAs significantly associated with clinical outcome in the training set. Fold-change was calculated as mean 
value in short survivors (SS) in respect to long survivors (LS). The last column shows whether the prognostic value of each 
miRNA was validated using TCGA data.
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Figure 3: Prognostic value of miR-99a, let-7c, and miR-125b cluster expression in two independent cohorts of 
mesothelioma. Patients with tumors with low expression of these miRNAs (low third) had significantly shorter OS compared with tumors 
with high expression (bottom two thirds) in: (A) training set (n=26) and (B) TCGA set (n=72).
Figure 4: Kaplan-Meier plots of overall survival according to risk index based on the expression of mir-99a, let-7c, and 
miR-125b. Patients whose tumors had high-risk score show significantly shorter median OS as compared with patients with low-risk in 
two independent cohorts: (A) training set and (B) validation set.
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median risk score value. Interestingly, patients with high-
risk had a shorter OS as compared to low-risk patients, and 
in the multivariate Cox model a high-risk score remained 
as an independent prognostic marker for OS.
Currently, a number of miRNAs have been 
correlated with prognosis in MPM patients [30–32]; 
in particular, Kirschner and colleagues and Lin and 
colleagues recently proposed the first prognostic miRNA 
signatures of surgically resected MPM patients [13, 
32]. The lack of overlap between our miRNA signature 
and their results might be explained by differences 
in the study population and in the methods used to 
measure miRNA expression and to normalize the data. 
Specifically, Kirschner and colleagues identified a 
miRNA signature in a cohort of patients who underwent 
EPP [13]; such signature was then validated in a group 
of patients subjected to P/D performed within a single 
institution. In contrast, our prognostic miRNA signature 
was developed in a cohort of unresected patients, and 
was identified by a high-throughput approach and then 
validated in two independent cohorts of patients. These 
differences underscore the need for building collaborative 
consortiums able to collect large cohorts of patients with 
mesothelioma to identify and validate robust markers for 
early diagnosis and prognosis. Overall, our results suggest 
that low expression of the 21q21.1 miRNA cluster could 
have a prognostic significance in unresected patients. 
However, a limitation of our study is the relatively low 
number of patients included in the VS mainly due to the 
fact that collecting samples from unresected MPM patients 
with long-term survival is challenging.
In conclusion, to the best of our knowledge, this 
is the first prognostic signature able to predict survival 
in patients who have not undergone surgery for MPM. 
Furthermore, identifying patients with different prognosis 
might guide clinical decisions whether to propose more 
aggressive or more conservative therapeutic approaches. 
Additionally, patients with an unfavorable miRNA 
signature could also benefit from novel therapeutic 
strategies in the future such as miRNA-based treatments, 
although further basic research is needed to verify the 
efficient translation of these approaches.
MATERIALS AND METHODS
Patient enrollment
In the present study, a total number of 27 patients 
diagnosed with MPM at the Istituto Nazionale per la 
Ricerca sul Cancro, Genova, Italy were enrolled as TS. In 
addition, 30 patients with clinically confirmed diagnosis 
of MPM were enrolled at San Andrea Hospital, La Spezia, 
Italy as VS. According to the clinical outcome, patients 
were divided into two groups: i) patients with SS, who 
died within 12 months from the diagnosis (TS: 15; VS: 16) 
and ii) LS patients whose OS was greater than 36 months 
(TS: 12; VS: 14). All patients who either underwent 
surgery or were older than 80 years at diagnosis were not 
eligible and hence excluded from the study.
Four additional biopsies of nonmalignant pleura 
obtained from healthy individuals were processed as 
a normal control (NC). The non-neoplastic controls of 
pleural tissue were obtained from surgical specimens 
of lobectomy performed for non-small cell lung cancer 
(NSCLC, 3 adenocarcinoma and 1 squamous cell 
carcinoma), in which portions of parietal pleura were 
present. At gross examination, all NSCLCs did not show 
pleural invasion and histologic sections of all pleural-
tissue samples were reviewed by the pathologist in order 
to rule out the presence of neoplastic cells.
The present study was approved by the institutional 
ethics committees (Istituto Nazionale per la Ricerca 
sul Cancro, Genova, Italy n. OT11.001, May 25, 2012 
for TS; Ethics Committee of the Liguria Region P.R. 
207REG2014, September 23, 2014 for VS), and conducted 
according to the provisions of the Declaration of Helsinki. 
The data were analyzed anonymously.
RNA and genomic DNA (gDNA) extraction
For each case, the FFPE biopsy tumor block was 
reviewed by the pathologist to check for the presence 
of adequate tumor cell content (>50%). Total RNA, 
including the miRNA fraction, was isolated from two 
FFPE macro-dissected tissue sections (10 μm) using the 
Recover All Total Nucleic Acid Isolation Kit for FFPE 
Tissue (ThermoFisher Scientific, Wilmington, DE, 
USA), including a RNase-free DNase I treatment. RNA 
quantity and quality were assessed by NanoDrop ND-
1000 (ThermoFisher Scientific) and 2100 Bioanalyzer 
instrument using RNA 6000 Nano Kit (Agilent 
Technologies, Santa Clara, CA, USA). All the samples that 
reported at least 150 ng of total RNA were defined suitable 
for further analyses. For 44 out of 57 patients enrolled in 
the study, two additional tumor sections (10 μm) were 
available to isolate gDNA using GeneRead DNA FFPE Kit 
(Qiagen, Hilden, Germany) that was quantified by Qubit® 
2.0 Fluorometer (ThermoFisher Scientific).
Microarray analysis
MiRNA profiling was performed on 27 MPMs 
from TS (15 SS and 12 LS) and 4 nonmalignant pleural 
samples. Total RNA containing miRNA was processed 
following the ‘miRNA Microarray System protocol’ v.2.4 
(Agilent Technologies), as previously described [33]. 
Briefly, 100 ng of total RNA and an appropriate dilution 
of Spike-in controls underwent dephosphorylation and 
labeling step with Cy3CTP and purification using Micro 
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Bio-Spin™ P-6 Gel Columns (Bio-Rad, Hercules, CA, 
USA). Then, each sample was hybridized on Human 
miRNA microarray slide 8x60K (miRBase Release 
19.0) (Agilent Technologies), including 2006 human 
miRNAs. After washing, the slides were scanned by 
G2565CA scanner (Agilent Technologies) and data 
were extracted by Feature Extraction software v.10 
(Agilent Technologies). Microarray expression data were 
normalized using GeneSpring software v.12.6 (Agilent 
Technologies). Microarray raw data have been deposited 
in Gene Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo/; GEO number: GSE92636) [34]. Missing values 
corresponding to each unexpressed miRNA were filled 
using the minimum value and then subtracting 0.5.
Validation of selected miRNAs using publicly 
available data
Clinical outcome and miRNAseq data were 
available from 72 patients with MPM included in the 
TCGA-Mesothelioma project, and these data were 
downloaded.
Analysis of genes targeted by select miRNAs
Validated genes targeted by select miRNAs 
were obtained from mirTarBase database [35]. An 
enriched pathway analysis was performed using DAVID 
functional annotation bioinformatics microarray analysis 
[36].
Validation of selected miRNAs by qPCR
Three selected miRNAs were then validated in a 
different set of tissue samples consisting of 30 patients 
from VS (16 SS and 14 LS) and 4 NC by qPCR using 
TaqMan® miRNA Assays (hsa-miR-99a #000435; hsa-
let-7c #000379; hsa-miR-125b #000449; U6 snRNA 
#001973 as reference miRNA; ThermoFisher Scientific). 
Briefly, 10 ng of total RNA were retro-transcripted into 
cDNA with a specific primer using TaqMan® MiRNA 
Reverse Transcription Kit (ThermoFisher Scientific). 
Then each selected miRNA was amplified in duplicate on 
RealPlex2 system (Eppendorf, Hamburg, Germany) using 
qPCR TaqMan® Universal Master Mix II, no Uracil-N 
glycoslyase (ThermoFisher Scientific) and normalized 
against U6 snRNA. The relative expression compared 
to the NC was determined using the equation 2-∆∆CT. 
A patient's risk score was calculated as the sum of the 
expression levels of the 3 selected prognostic miRNAs 
in the VS, weighted by the corresponding regression 
coefficients (β) derived from the Cox regression analysis 
in the TS, as previously reported [14]. The risk score was 
used to classify patients into high- or low-risk groups, with 
a high-risk score indicating poorer survival. In the VS, the 
median of the risk score was used as the cutoff value.
Copy number determination of the miR-99a/let-
7c/miR-125b locus
The CNV study of the miR-99a/let-7c/miR-
125b locus (21q21.1) was assessed in both TS and VS 
tumor samples by ddPCR according to the multiplexing 
strategy (three targets quantified in a triplex reaction) 
[37]. Specifically, custom FAM-labeled miR-99a/
let-7c/miR-125b assay (dHsaCNS694336600) was 
normalized with two HEX-labeled assays as follows: 
RBM11 (dHsaCP2506724) targeting the centromere 
locus on chromosome 21 and AP3B1 (dHsaCP2500348) 
mapping on 5q14.1 (Bio-Rad). Briefly, the ddPCR 
reaction including 20 ng of gDNA, Bio-Rad ddPCR 
supermix for Probes No dUTP and the labeled TaqMan 
assays (miR-99a/let-7c/miR-125b locus assay at 100% 
of concentration, RBM11 100% and AP3B1 50%) were 
converted in approximately 15,000 droplets using the 
QX200 Droplet Generator and amplified according to the 
Bio-Rad standard protocol (60°C as annealing/extension 
temperature). The amplified samples were then acquired 
by QX100 Droplet Reader and the data were analyzed 
using QuantaSoftTM Analysis Pro software v.1.0.596 (Bio-
Rad). Each sample was run in duplicate with a wild type 
sample and negative control (no template) and the CNV 
of the miR-99a/let-7c/miR-125b locus was calculated as 
the ratio between the concentration (copies/μl) of the miR-
99a/let-7c/miR-125b locus and the mean concentration 
value of RBM11 and AP3B1, multiplied by 2. Data were 
obtained as the result of two technical replicate wells. 
CNV values higher than 2.5 or lower than 1.5 were defined 
as amplified or deleted locus.
Statistical analysis
Class-comparison analysis between MPM/NC 
and SS/LS was performed using a receiver operating 
characteristic (ROC) curve and the non-parametric Mann-
Whitney U test. Survival curves were plotted using the 
Kaplan–Meier method, and survival differences were 
assessed by the log-rank test using the median of each 
individual miRNA as a cutoff. Univariate or multivariate 
Cox proportional hazards were calculated considering 
individual miRNA as a continuous variable. Multivariate 
analysis was adjusted by age and histological subtype. 
All calculations were performed using SPSS Statistics 
package v.15.0.
Abbreviations
CNV: copy number variation; ddPCR: droplet 
digital polymerase change reaction; EPP: extra-pleural 
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